期刊
MODERN RHEUMATOLOGY
卷 19, 期 1, 页码 69-72出版社
TAYLOR & FRANCIS LTD
DOI: 10.1007/s10165-008-0116-2
关键词
Anti-IL-6 receptor antibody; Biologics; IL-6; Remission; AOSD
类别
资金
- Chugai Pharmaceutical Co., Ltd.
Interleukin-6 overproduction is pathologically involved in adult onset Still's disease (AOSD). We successfully treated a man with refractory AOSD utilizing tocilizumab. Tocilizumab was discontinued after 15 doses due to intestinal bleeding, but the efficacy was sustained over 21 months. Tocilizumab was readministered safely upon recurrence and showed similar efficacy over 6 years. Corticosteroid and NSAIDs could be discontinued and intestinal bleeding was no more observed. Tocilizumab can be a therapeutic option for AOSD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据